The MWC has four Emeritus Principal Investigators who were all founding members of the centre and have a wealth of experience in managing large collaborative research programmes. They are recognised internationally as leaders in their respective fields.
Emeritus Principal Investigators
Distinguished Professor Ted BakerCNZM, MSc, PhD, FRSNZ, FNZIC email@example.com
Distinguished Professor Ted Baker established structural biology in New Zealand with his pioneering work at Massey University on the proteins actinidin and lactoferrin.
Among Ted's national and international honours are an International Research Scholar award from the Howard Hughes Medical Institute and election as President of the International Union of Crystallography. He has received the 2006 Rutherford Medal, the highest accolade from the Royal Society of New Zealand, and the 2008 Liley Medal for Health Research, and has been appointed a Companion of the New Zealand Order of Merit.
Professor Baker now leads a group of researchers at the University of Auckland who combine the analysis of protein structure and function by X-ray crystallography with elements of structural genomics, molecular biology, bioinformatics, protein engineering and structure-based drug design. His current interests focus primarily on infectious disease, in particular tuberculosis and streptococcal disease.
Professor Garth CooperDSc (Oxon), DPhil (Oxon), MB, ChB, FRCPA, FRSNZ, FMedSci (London) firstname.lastname@example.org
Professor Garth Cooper, professor of Biochemistry & Clinical Biochemistry, School of Biological Sciences, and Department of Medicine, Faculty of Medical and Health Sciences, is distinguished by his contributions to the molecular pathophysiology and experimental therapeutics of diabetes mellitus for which he was elected a Fellow of the Academy of Medical Sciences (UK) in 2013, based on exceptional contributions to the medical sciences.
Professor Cooper discovered amylin, the pancreatic islet β-cell hormone that constitutes islet amyloid in type-2 diabetes, and invented amylin replacement therapy (the amylin agonist, ‘pramlintide’) as a new treatment for this disease, registered by the USFDA in 2005 for the treatment of both major types of diabetes. He is also Director and Professor of Discovery & Experimental Medicine, Centre for Advanced Discovery & Experimental Therapeutics (CADET), University of Manchester, UK. His teams work in parallel in both nonclinical models and human clinical trials, applying powerful techniques aimed at understanding the molecular basis of ageing-related diseases, particularly diabetes, heart failure, and dementia.